Nayan Arora,MD (@captainchloride) 's Twitter Profile
Nayan Arora,MD

@captainchloride

Nephrologist @UWNephrology | Runner, dad, whiskey drinker | #NSMC | @FreelyFiltered | #cardiorenal enthusiast | Tweets my own.

ID: 931340760

linkhttps://nephrology.uw.edu/people/faculty/arora-n calendar_today07-11-2012 05:57:51

2,2K Tweet

3,3K Followers

938 Following

Nayan Arora,MD (@captainchloride) 's Twitter Profile Photo

Whenever I get frustrated with my patients for seeking cures with alternative medicine I have to remind myself that bloodletting was a physicians go to move for decades

Nayan Arora,MD (@captainchloride) 's Twitter Profile Photo

#cardstwitter - if cardiac power is such an important variable then would afterload reduction only be effective in those with secondary MR or is influence on CO stronger than the influence on MAP? Or am I just thinking about this completely incorrectly? sciencedirect.com/science/articl….

Nayan Arora,MD (@captainchloride) 's Twitter Profile Photo

Wait torsemide has less kidney bioavailability than furosemide and the appropriate PO ratio between them is actually 4:1? 🤯 journals.lww.com/jasn/pages/art…

Nayan Arora,MD (@captainchloride) 's Twitter Profile Photo

Patient with an eGFR of 20, HF, significantly volume overloaded. They are going to get a CT angiogram. To reduce the risk of contrast associated nephropathy (this is not a discussion on if it exists or not) do you: #nephtwitter

Nayan Arora,MD (@captainchloride) 's Twitter Profile Photo

I am (was?) a believer that finerenone is essentially low dose spironolactone. This study challenges that showing no ⬇️ in CV events with low dose spironolactone in patients with CKD 3b. Lots of recruitment issues but hard to put this up against Figaro. nature.com/articles/s4159…

I am (was?) a believer that finerenone is essentially low dose spironolactone. This study challenges that showing no ⬇️ in CV events with low dose spironolactone in patients with CKD 3b. Lots of recruitment issues but hard to put this up against Figaro.

nature.com/articles/s4159…